Transderm scop and Depression aggravated - a phase IV clinical study of FDA data

Summary:

Depression aggravated is reported as a side effect among people who take Transderm scop (scopolamine), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Celebrex, and have Narcolepsy.

The phase IV clinical study analyzes which people have Depression aggravated when taking Transderm scop. It is created by eHealthMe based on reports of 2,949 people who have side effects when taking Transderm scop from the FDA, and is updated regularly.

What is Transderm scop?

Transderm scop has active ingredients of scopolamine. It is often used in motion sickness. eHealthMe is studying from 3,011 Transderm scop users. Check the latest studies of Transderm scop.

What is Depression aggravated?

Depression aggravated is found to be associated with 2,403 drugs and 750 conditions by eHealthMe. Check the latest studies of Depression aggravated.

On Aug, 04, 2026

2,949 people reported to have side effects when taking Transderm scop.
Among them, 48 people (1.63%) have Depression aggravated.

Could Transderm scop cause Depression aggravated?

Among these 48 people:

How long have people been on Transderm scop when they have Depression aggravated? *

What is the gender of people who have Depression aggravated when taking Transderm scop? *

female: 86.96 %
male: 13.04 %

What is the age of people who have Depression aggravated when taking Transderm scop? *

What are other drugs people take besides Transderm scop? *

What are other side effects people have besides Depression aggravated? *

Stress And Anxiety: 25 people, 52.08%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 10 people, 20.83%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 10 people, 20.83%
Osteomyelitis (infection of bone): 9 people, 18.75%
Renal Disorder (kidney disease): 8 people, 16.67%
Nausea (feeling of having an urge to vomit): 8 people, 16.67%
Pain: 7 people, 14.58%
Ureteric Stenosis (abnormal narrowing or contraction of a duct or canal): 7 people, 14.58%
Blood Prolactin Decreased: 7 people, 14.58%
Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 7 people, 14.58%

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 12 people, 25.00%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 10 people, 20.83%
Pain: 6 people, 12.50%
Nausea (feeling of having an urge to vomit): 6 people, 12.50%
Fibromyalgia (a long-term condition which causes pain all over the body): 4 people, 8.33%
Osteoporosis (bones weak and more likely to break): 4 people, 8.33%
High Blood Cholesterol: 3 people, 6.25%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 6.25%
Diabetes: 3 people, 6.25%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Transderm scop and have Depression aggravated?

- Check whether Depression aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Transderm scop:

Transderm scop (3,011 reports)

Browse all side effects of Transderm scop:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Depression aggravated:

Depression aggravated (2,403 drugs)

Browse all the conditions that are associated with Depression aggravated:

Depression aggravated (750 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on scopolamine (the active ingredients of Transderm scop) and Transderm scop (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.